Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Hughes

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
JTO Clinical and Research Reports|August 1, 2025
Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted AgentsAnne C Chiang, Russell W Madison, Zoe June Assaf, et al.
Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.
JCO Precision Oncology|September 28, 2023
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor ResponseJay A Moore, Kuei-Ting Chen, Russell Madison, et al.
Journal of Gastrointestinal Oncology|October 12, 2019
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsyGerald Li, Dean Pavlick, Jon H Chung, et al.
Plos One|May 16, 2024
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumorsDaniel R Zollinger, Elizabeth Rivers, Alexander Fine, et al.
Science (New York, N.Y.)|September 13, 2014
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4Hye Sun Kuehn, Weiming Ouyang, Bernice Lo, et al.
Blood Advances|September 28, 2022
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasmsJack Chovanec, Ilker Tunc, Jason Hughes, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
JTO Clinical and Research Reports|August 1, 2025
Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted AgentsAnne C Chiang, Russell W Madison, Zoe June Assaf, et al.
Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.
JCO Precision Oncology|September 28, 2023
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor ResponseJay A Moore, Kuei-Ting Chen, Russell Madison, et al.
Journal of Gastrointestinal Oncology|October 12, 2019
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsyGerald Li, Dean Pavlick, Jon H Chung, et al.
Plos One|May 16, 2024
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumorsDaniel R Zollinger, Elizabeth Rivers, Alexander Fine, et al.
Science (New York, N.Y.)|September 13, 2014
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4Hye Sun Kuehn, Weiming Ouyang, Bernice Lo, et al.
Blood Advances|September 28, 2022
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasmsJack Chovanec, Ilker Tunc, Jason Hughes, et al.
Pageof 3